Innovation in Oncology, Cell & Gene Technology, and Post-COVID-19 Pharma Outlook to be Discussed by Catalent at the CPhI Festival of Pharma
SOMERSET, N.J. – October 6, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will be participating in several roundtables alongside other leading industry experts at the CPhI Festival of Pharma, which is taking place virtually between Oct. 5 – 16, 2020.
On Oct. 14 at 2 p.m. CET, Julien Meissonnier, Chief Scientific Officer, Catalent, will participate in a roundtable session titled, “Innovation in Oncology Development”. Moderated by Yasemin Karanis, Consultant, Thought Leadership, IQVIA, the roundtable panelists will discuss the current drug pipeline as well as new approaches to drug development for oncology, including nanotechnology, immunotherapy and targeted therapies.
On Oct. 16 at 2 p.m. CET, Thomas VanCott, Ph.D., Global Head of Product Development, Catalent Cell & Gene Therapy, will participate in the “Cell & Gene Technology” roundtable session. Alongside the other panelists, Dr. VanCott will discuss innovative technologies and process platforms across the cell and gene scale-up and production process, and product development. The panelists will also consider how technology integrators can increase efficiency and standardization in cell and gene production.
On Oct. 16 at 4 p.m. CET, Cornell Stamoran, Ph.D., Vice President of Corporate Strategy, and founder of the Catalent Applied Drug Delivery Institute (“Catalent Institute” – www.drugdeliveryinstitute.com), will join other invited participants in an Executive Leadership Roundtable, titled “Facing the COVID-19 Crisis: Leadership and the Future of Pharma”, moderated by Stephanie Sutton, the Editor of The Medicine Maker. The panelists will discuss the strategies implemented to minimize the impact of COVID-19 on their businesses, and consider the future outlook of the pharmaceutical industry.
The Festival of Pharma will include the annual CPhI Awards, and this year, Catalent has been shortlisted in the “Innovation in Response to COVID-19” category. On Oct. 12 at 4 p.m. CET, Kay Schmidt, Senior Vice President, Technical Operations, will present an overview of the company’s COVID-19 response. During the show, Catalent will also participate in the virtual exhibition and showcase its multiple drug development and delivery technology solutions.
Mr. Meissonnier leads the company’s scientific community and its customer advisory partnerships. He is responsible for Catalent’s new product development and technology innovation programs, and co-chairs the Catalent Institute, which leverages emerging new therapeutic modalities. Mr. Meissonnier holds an engineering degree in physico-chemistry from the ENSI in Caen, France.
Dr. VanCott joined Catalent through its acquisition of Paragon Gene Therapy in 2019. Prior to Paragon he spent 14 years as the President and Chief Executive Officer of Advanced Bioscience Laboratories Inc. (ABL), and previously held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. Dr. VanCott received a doctorate in physical chemistry from the University of Virginia, and a bachelor’s degree in chemistry from Dickinson College, Carlisle, Pennsylvania.
Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of the Catalent Institute. He has spent more than 30 years engaged in the healthcare industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.
Ms. Schmidt joined Catalent in 2009 and has held several leadership roles in product development across multiple drug delivery dosage forms. Most recently, she provided leadership to Catalent’s senior, multi-disciplinary Coronavirus Response Team. She is a certified Six Sigma Green Belt, and has a bachelor’s degree from Carroll University, Wisconsin and a master’s degree from the University of Wisconsin-Whitewater.
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com